B Charpentier

A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

Flavio Vincenti, B Charpentier, Yves Vanrenterghem et al. · American Journal of Transplantation · 2010 · 931 citations

Transplant Rejection, Urology, Transplantation +13

Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients

Flavio Vincenti, Christian P. Larsen, Josefina Alberú et al. · American Journal of Transplantation · 2011 · 308 citations · Full text

Risk Factors and Long-Term Outcome of Transplant Renal Artery Stenosis in Adult Recipients After Treatment by Percutaneous Transluminal Angioplasty

Vincent Audard, Marie Matignon, F. Hémery et al. · American Journal of Transplantation · 2005 · 176 citations

Transplantation Surgery, Urology, Kidney Transplant +10

Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study

Bernhard K. Krämer, B Charpentier, Lars Bäckman et al. · American Journal of Transplantation · 2010 · 164 citations · Full text

Tacrolimus Once Daily, Urology, Transplantation +10

FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia

Maurizio Salvadori, Klemens Budde, B Charpentier et al. · American Journal of Transplantation · 2006 · 147 citations · Full text

Bpar Incidence, Transplantation Medicine, Immunology +17